PharmAust says its MPL drug has a long and stable shelf life

Independent tests have shown PharmAust’s Monepantel (MPL) anti-cancer drug retains long-term shelf life and product stability.

The Good Manufacturing Practice (GMP) grade stability study conducted independently by Catalent Pharma Solutions (NYSE:CTLT) was for a storage period of at least 12 months.

GMP is a globally recognised standard which requires rigorous, controlled and documented processes to provide fully-characterised drugs with the highest levels of purity for safe and effective administration to patients – and meets the standards required for clinical trials in Australia, the United States and Europe.

GMP tablet reduces costs and risks

It’s kind of a big deal for the biotechnology company, as it moves towards Phase 2 human trials and identifies potential commercial partners.

“We are delighted with the latest stability achievements in the development of monepantel,” PharmAust (ASX:PAA) executive chairman Dr Roger Aston said.

“Having a robust GMP tablet significantly reduces costs and risk associated with repeat manufacturing programs and provides more certainty for PharmAust’s clinical trial scheduling.”

FightMND milestone payment

PharmAust (ASX:PAA) teamed up with Aussie charity organisation, FightMND, a few years ago to conduct research into Motor neurone disease (MND) with the help of a $900k grant.

With the completion of this 12-month GMP Stability Study, the next instalment of $118,926.80 is now payable, the company says.

A further $138,134.80 will be payable upon the completion of Cohort 3 which is expected next month, and $150,142.80 will be payable upon the completion of Cohort 4 which is expected in July 2023.

 

 

 

This article was developed in collaboration with PharmAust Limited, a Stockhead advertiser at the time of publishing.

 

This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.

Related Topics

Explore more

Explore more

Investor Guide: Health & Biotech FY2025 featuring Tim Boreham

Read The Guide